Volume 6.07 | Feb 27

Cord Blood News 6.07 February 27, 2014
Cord Blood News
     In this issue: Publications | Reviews | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook  Cord Blood News on Twitter
 
TOP STORY
Human Growth Hormone Promotes Megakaryocyte Differentiation and Exerts a Complementary Effect with c-Mpl Ligands on Thrombopoiesis
Investigators showed for the first time that human growth hormone has a distinct capacity to promote the differentiation of human primary megakaryocytes derived from umbilical cord blood CD34+ cells. [Blood] Abstract
Technical Bulletin: Assays For Cord Blood
 
PUBLICATIONS (Ranked by impact factor of the journal)
Angiopoietin-Like Protein 2 Regulates Endothelial Colony Forming Cell Vasculogenesis
The authors sought to investigate the potential role of Angiopoietin-like 2 (ANGPTL2) in regulating human cord blood derived endothelial colony forming cell vasculogenesis through siRNA mediated inhibition of ANGPTL2 gene expression. [Angiogenesis] Abstract

Equine Mesenchymal Stem Cells from Bone Marrow, Adipose Tissue and Umbilical Cord: Immunophenotypic Characterization and Differentiation Potential
Researchers evaluated the cell culture and immunophenotypic characteristics and differentiation potential of equine mesenchymal stem cells from bone marrow, adipose tissue and umbilical cord under identical in vitro conditions, to compare these sources for research or an allogeneic therapy cell bank. [Stem Cell Res Ther] Abstract | Full Article

Human Wharton’s Jelly-Mesenchymal Stem Cells Promote Skin Wound Healing through Paracrine Signaling
Mesenchymal stem cells (MSCs) have been reported to provide paracrine signals to promote wound healing, but the effect of human Wharton’s jelly-derived MSCs (WJ-MSCs) has not yet been described in human normal skin. Scientists examined the effects of human WJ-MSC paracrine signaling on normal skin fibroblasts in vitro, and in an in vivo preclinical model. [Stem Cell Res Ther] Abstract | Full Article

Good Manufacturing Practice-Compliant Isolation and Culture of Human Umbilical Cord Blood-Derived Mesenchymal Stem Cells
The applications of umbilical cord blood-derived mesenchymal stem cells (UCB-MSCs) are limited by the small number of recoverable UCB-MSCs and fetal bovine serum-dependent expansion methods. Hence, researchers aimed to establish a xenogenic and allogeneic supplement-free expansion protocol. [J Transl Med]
Abstract | Full Article

Umbilical Cord-Derived Mesenchymal Stem Cells Regulate Thymic Epithelial Cell Development and Function in Foxn1-/- Mice
Scientists used human umbilical cord-derived mesenchymal stem cells to treat forkhead box n1 (Foxn1)-/- mice, and then analyzed the maturation and distribution of thymic epithelial cells in the Foxn1-/- thymic rudiment and the thymopoiesis of this newly developed rudiment. [Cell Mol Immunol] Abstract

Umbilical Cord Blood Cells Regulate the Differentiation of Endogenous Neural Stem Cells in Hypoxic Ischemic Neonatal Rats via the Hedgehog Signaling Pathway
Researchers explored the effects of umbilical cord blood mononuclear cell transplantation on the differentiation of endogenous neural stem cells and their underlying mechanisms. [Brain Res] Abstract

Improving Viability and Transfection Efficiency with Human Umbilical Cord Wharton’s Jelly Cells Through Use of a ROCK Inhibitor
Investigators hypothesized that Rho-associated coiled-coil kinase (ROCK) inhibitor would improve cell viability and gene expression in primary human umbilical cord mesenchymal stromal cells when transfected via Nucleofection™. [Cell Reprogram] Abstract

Mechanisms of Paracrine Cardioprotection by Cord Blood Mesenchymal Stromal Cells
Scientists investigated the non-regenerative cardioprotective effects of cord blood mesenchymal stromal cells in vitro and sought to identify relevant intracellular signaling pathways. [Eur J Cardiothorac Surg] Abstract

New Cord Banking Software Solution from STEMSOFT
 
REVIEWS
Umbilical Cord Mesenchymal Stem Cells: The New Gold Standard for Mesenchymal Stem Cell Based Therapies?
In this review, the authors aimed to synthesize the differences between umbilical cord-mesenchymal stromal cells (MSCs) and MSCs from other sources concerning their proliferation capacity, proteic and transcriptomic profiles and their secretome involved in their regenerative, homing and immunomodulatory capacities. [Tissue Eng Part B Rev] Abstract

Cord Blood Banking and Transplantation: Advances and Controversies
A review of articles published since January 2012 on the topic of cord blood banking and cord blood stem cell transplantation was conducted for this the 25th anniversary year of the first cord blood transplant performed in a human. [Curr Opin Pediatr] Abstract

Visit our reviews page to see a complete list of reviews in the cord blood research field.
 
INDUSTRY NEWS
Fate Therapeutics Announces Observed Effects of Pharmacologic Modulation on T Cell Compartment from Its Phase Ib Study of PROHEMA(R)
Fate Therapeutics, Inc. announced the release of new data on the observed effects of ex vivo pharmacologic modulation on CD8+ T cells and immune reconstitution from its previously-completed Phase Ib clinical trial of PROHEMA® (16, 16-dimethyl prostaglandin E2, or dmPGE2, modulated cord blood) in adult patients undergoing hematopoietic stem cell transplantation for hematologic malignancy (the ProHema-01 trial). [Fate Therapeutics, Inc.] Press Release

Pluristem Receives Key 3D Cell Expansion Patent in Australia
Pluristem Therapeutics, Inc. announced it has been granted a new patent by the Australian Patent Office. Patent #2007228341 covers the method and composition of matter for three-dimensional (3D) expansion of placental or adipose stromal cells, Pluristem’s key technology platform. [Pluristem Therapeutics, Inc.] Press Release

New Center in Nottingham to Collect Life-Saving Umbilical Cord Blood
Anthony Nolan opened two new cord blood collection centers in Queen’s Medical Centre and Nottingham City Hospital, thanks to funding from the Government’s Regional Growth Fund. [Anthony Nolan] Press Release

GE Capital Provides Credit Facility to SynGen, Inc.
GE Capital, Healthcare Financial Services announced that it has recently provided a $2.5 million senior secured credit facility to SynGen, Inc., a medical device company with a 510(k) approved bench-top system for isolating stem cells from umbilical cord blood, peripheral blood and bone marrow. [GE Capital, Healthcare Financial Services] Press Release

From our sponsor:
View immunology lectures, protocols and other resources on the Human Immunology Portal.
 
POLICY NEWS
National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)
 
EVENTS
NEW Stem Cells and Regenerative Medicines Congress Asia
October 21-23, 2014
Seoul, South Korea

NEW Cell Culture World Congress Asia
October 21-23, 2014
Seoul, South Korea

Visit our events page to see a complete list of events in the cord blood community.
 
JOB OPPORTUNITIES
NEW PhD Studentship – Stem Cell Research (University Medical Center Ulm)

Postdoctoral Position – Hematopoietic Stem Cell Self-Renewal (University of Iowa)

Director – Clinical Immunogenetics Laboratory (Fred Hutchinson Cancer Research Center)

Postdoctoral Position – Hematopoietic Stem Cell Biology (St. Jude Children’s Research Hospital)

Postdoctoral Positions – Hematopoietic Stem Cell Physiology and Bone Marrow Failure (University of Michigan)

Assistant Professorship – Hematopoietic Stem Cells and Microenvironment (University of Zurich)

Postdoctoral Fellow – Morphogenetic Signaling Pathways in Development and Disease (University of Rochester Medical Center)

Research Technologist – Pluripotent Stem Cells (STEMCELL Technologies Inc.)

Research Technologist – Particle Chemistry (STEMCELL Technologies Inc.)

Research Technologist – PSC Biology and Bioengineering (STEMCELL Technologies Inc.)


Recruit Top Talent: Reach more than 50,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.
 

Have we missed an important article or publication in Cord Blood News? Click here to submit!

Comments or suggestions? Submit your feedback here
Learn more about Cord Blood News: Archives | Events | Contact Us